Sanofi-sponsored Scientific Abstracts and Presentations from the American Diabetes Association (ADA) 81st Annual Scientific Sessions

A Virtual Experience

June 25-29, 2021

Insulin glargine U100/lixisenatide 33 mcg/mL

1-LB: Advancing Therapy in Basal Insulin Users with Type 2 Diabetes (T2D): Hypoglycemia as a Function of HbA1c in the SoliMix Trial

McCrimmon RJ, Home P, Cheng AY, Giorgino F, Fonseca V, Souhami E, Alvarez A, Boss AH, Melas-Melt L, Rosenstock J

234-OR: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Better Clinical Outcomes with iGlarLixi vs. Premix 70/30 in the SoliMix Trial

Rosenstock J, Emral R, Sauque-Reyna L, Mohan V, Trescolí C, Al Sifri S, Lalic N, Alvarez A, Picard P, Demil N, Bonnemaire M, McCrimmon RJ, on behalf of the SoliMix Trial Investigators

746-P: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Nocturnal hypoglycemia in the SoliMix trial

McCrimmon RJ, Cheng AY, Fonseca V, Choza-Romero R, Al Essa T, Alvarez A, Souhami E, Boss AH, Picard P, Rosenstock J

748-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial in Participants in Europe

Cheng AY, McCrimmon RJ, Fonseca V, Trescolí C, Haluzík M, Seufert J, Alvarez A, Souhami E, Picard P, Bonnemaire M, Rosenstock J

749-P: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe

Fonseca V, Rosenstock J, Cheng AY, Emral R, Sauque-Reyna L, Mohan V, Al Sifri SN, Alvarez A, Djaballah K, Picard P, Souhami E, McCrimmon RJ

Insulin glargine U300

Diabetes management

1033-P: Complications at One Year in a Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India (LANDMARC)

Rais N, Das AK, Joshi S, Mithal A, Kalra S, Unnikrishnan A, Thacker H, Sethi B, Chowdhury S, Ghosh R, Krishnan S, Nair A, Mohanasundaram S, Menon SK, Salvi V, Chodankar D, Trivedi C, Wangnoo S, Zargar AH, Kumar K

1041-P: Diabetes Complications Among Patients from Metropolitan vs. Non-Metropolitan Cities in India: One-Year Results of LANDMARC

Kalra S, Das AK, Joshi S, Mithal A, Kumar K, Unnikrishnan A, Thacker H, Sethi B, Chowdhury S, Ghosh R, Krishnan S, Nair A, Mohanasundaram S, Menon SK, Salvi V, Chodankar D, Trivedi C, Wangnoo SK, Zargar AH, Rais N

1065-P: Glycemic Trend at One Year in a Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India (LANDMARC)

Joshi S, Das AK, Kumar K, Mithal A, Kalra S, Unnikrishnan A, Thacker H, Sethi B, Chowdhury S, Ghosh R, Krishnan S, Nair A, Mohanasundaram S, Menon SK, Salvi V, Chodankar D, Trivedi C, Wangnoo S, Zargar AH, Rais N

1087-P: Therapy Trends at One Year in the Longitudinal LANDMARC Study on Real-World Outcomes in Type 2 Diabetes Patients in India

Thacker H, Das AK, Joshi S, Mithal A, Kalra S, Unnikrishnan A, Kumar K, Sethi B, Chowdhury S, Ghosh R, Krishnan S, Nair A, Mohanasundaram S, Menon SK, Salvi V, Chodankar D, Trivedi C, Wangnoo S, Zargar AH, Rais N

1095-P: Glycemic Trend in Metropolitan vs. Non-Metropolitan Cities of India: One-Year Results of LANDMARC

Unnikrishnan A, Das AK, Joshi S, Mithal A, Kalra S, Kumar K, Thacker H, Sethi B, Chowdhury S, Ghosh R, Krishnan S, Nair A, Mohanasundaram S, Menon SK, Salvi V, Chodankar D, Trivedi C, Wangnoo S, Zargar AH, Rais N

Information is provided for scientific purposes only and may be outside the current labelling of the product. Sanofi does not recommend the use of any products in any manner inconsistent with that described in the full prescribing information. Please consult the prescribing information in your country of practice, as it can vary from country to country.

Availability of posters and/or abstracts on this site will coincide with ADA’s embargo policy.